Aurora A overexpression and pVHL reduced expression are correlated with a bad kidney cancer prognosis

Disease Markers

Volumn 33, Issue 6, 2012, Pages 333-340

  Ferchichi, Imen ^a   Kourda, Nadia ^b   Sassi, Samia ^c   Romdhane, Khaled Ben ^c   Balatgi, Sarra ^b   Cremet, Jean Yves ^d   Prigent, Claude ^d   Elgaaied, Amel Benammar ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c SALAH AZAIEZ INSTITUTE   (Tunisia)

^d UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Aurora A; immunohistochemistry; kidney cancer; pVHL

Indexed keywords

AURORA A KINASE; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER SIZE; CARCINOMA CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 84872284668     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2012/804708     Document Type: Article

References (48)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma, Lancet 373 (2009), 1119-1132.
2. Motzer R, Bander N, Nanus D. Renal cell carcinoma, Medical Prog 335 (1996), 865-875.
3. Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma, Clin Dev Immunol (2010), 284581.
4. Hollenbeak CS, Nikkel LE, Schaefer EW, Alemao E, Ghahramani N, Raman JD. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma, J Manag Care Pharm 17(8) (2011), 610-620.
5. Thoma CR, Toso A, Meraldi P, KrekW. Double-trouble in mitosis caused by von Hippel-Lindau tumor-suppressor protein inactivation. Cell Cycle 8(22) (2009), 3619-3620.
6. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer, Clin Cancer Res 14(14) (2008), 4455-4462.
7. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A, Stassi G. Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells, Cancer Res 70(11) (2010), 4655-4665.
8. Rugge M, Fassan M, Zaninotto G, Pizzi M, Giacomelli L, Battaglia G, Rizzetto C, Parente P, Ancona E. Aurora kinase A in Barrett's carcinogenesis, Hum Pathol 41(10) (2010), 1380-1386.
9. Lassus H, Staff S, Leminen A, Isola J, Butzow R. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma, Gynecol Oncol 120(1) (2011), 11-17.
10. EharaH,Yokoi S, Tamaki M, NishinoY, TakahashiY, Deguchi T, Kimura M, Yoshioka T, Okano Y. Expression of mitotic Aurora/Ipl1p-related kinases in renal cell carcinomas: an immunohistochemical study, Urol Res 31(6) (2003), 382-386.
11. Kurahashi T, Miyake H, Hara I, Fujisawa M. Significance of Aurora-A expression in renal cell carcinoma, Urologic Oncology: Seminars and Original Investigations 25 (2007), 128-133.
12. Mathieu R, Patard JJ, Stock N, Rioux-Leclercq N, Guilĺe F, Fergelot P, Bensalah K. Study of the expression of Aurora kinases in renal cell carcinoma, Prog Urol 20(13) (2010), 1200-1205.
13. Cowley DO, Rivera-Ṕerez JA, Schliekelman M, He YJ, Oliver TG, Lu L, O'Quinn R, Salmon ED,Magnuson T, Van Dyke T. Aurora-A kinase is essential for bipolar spindle formation and early development, Mol Cell Biol 29(4) (2009), 1059-1071.
14. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/-cells, Embo J 21 (2002), 483-492.
15. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis, Mol Cancer Res 5(1) (2007), 1-10.
16. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilizationand inhibition of p53, Nat Genet 36 (2004), 55-62.
17. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215, J Biol Chem 279 (2004), 52175-52182.
18. Xu J, Li H, Wang B, Xu Y, Yang J, Zhang X, Harten SK, Shukla D,Maxwell PH, Pei D, EstebanMA. VHL inactivation induces HEF1 and Aurora kinase A, J Am Soc Nephrol 21(12) (2010), 2041-2046.
19. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene, Science 260 (1993), 1317-1320.
20. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma, Clin Cancer Res 13 (2007), 680-684.
21. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, Knowles M, Selby PJ. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer, Cancer Res 66 (2006), 2000-2011.
22. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat Genet 7 (1994), 85-90.
23. Brauch H,Weirich G, Brieger J, Glavac D, R̈odl H, Eichinger M, Feurer M,Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Sẗorkel S, Rotter M, Masera A, Gugeler N, Decker HJ. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation, Cancer Res 60 (2000), 1942-1948.
24. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, NavratilovaM, Szeszenia-Dabrowska N,Mates D,Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors, Clin Cancer Res 14 (2008), 4726-4734.
25. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W,Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma, Clin Cancer Res 15 (2009), 7582-7592.
26. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O. The Von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix, Mol Cell 1 (1998), 959-968.
27. Roe JS, Youn HD. Extra view the positive regulation of p53 by the tumor suppressor VHL, Cell Cycle 5 (2006), 2054-2056.
28. Pause A, Lee S, Lonergan KM, Klausner RD. TheVon Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal, Proc Natl Acad Sci USA 95(3) (1998), 993-998.
29. Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE. The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery, Exp Cell Res 301(2) (2004), 139-146.
30. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the Von Hippel-Lindau tumour suppressor protein pVHL, Nat Cell Biol 5 (2003), 64-70.
31. Kuehn EW, Walz G, Benzing T. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development, Cancer Res 67(10) (2007), 4537-4540.
32. Sinha S, Mondal G, Hwang EJ, Han da W, Dutta SK, Iyer S, Karumanchi SA, Kim KI, Couch FJ, Mukhopadhyay D. Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function, J Cell Sci 124 (2011), 2132-2142.
33. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, Hergovich A,Moch H,Meraldi P, KrekW. VHL loss causes spindle misorientation and chromosome instability, Nat Cell Biol 11(8) (2009), 994-1001.
34. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer, J Clin Oncol 22(24) (2004), 4991-5004.
35. Yuen JSP. Molecular targeted therapy in advanced renal cell carcinoma: a review of its recent past and a glimpse into the near future, Indian J Urol 25 (2009), 427.
36. Rajaganeshan R, Prasad PJ, Guillou N, Scott G, Poston DG. Jayne Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases, Eur J Surg Oncol 35(12) (2009), 1286-1294.
37. Chen L, Ao X, Ren Q, Wang ZN, Lu C, Xu Y, Jiang L, Luo Y, Xu HM, Zhang XYi. Linkage disequilibrium and haplotype analysis of two single nucleotide polymorphisms in STK15 in Chinese, Yi Chuan Xue Bao 32(4) (2005), 331-336.
38. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma, Nat Rev Clin Oncol 7(5) (2010), 277-288.
39. Schraml P, Hergovich A, Hatz F, Amin MB, Lim SD, Krek W,Mihatsch MJ,Moch H. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression, Am J Pathol 163(3) (2003), 1013-1020.
40. Horng-Yih Shiao, Forsti A, Egevad L, Anderson LM, Lindblad P, Hemminki K. VHL down-regulation and differential localization as mechanisms in tumorigenesis, Kidney Int 64(5) (2003), 1671-1674.
41. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues, Hum Pathol 4 (1997), 459-464.
42. Cremet J Y, Descamps S, V́erit́e F,Martin A, Prigent C. Preparation and characterization of a human aurora-A kinase monoclonal antibody, Mol Cell Biochem 243 (2003), 123-131.
43. Ficarra V, Brunelli M, Cheng L, et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors, Eur Urol 58 (2010), 655-668.
44. Altaf Dar A, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W. Frequent overexpression of Aurora KinaseAin upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions, Cancer 112(8) (2008), 1688-1698.
45. Lin F, Shi J, Liu H, Zhang J, Zhang PL, Wang HL, Yang XJ, Schuerch C. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus, Am J Clin Pathol 129(4) (2008), 592-605.
46. Iliopoulos O, OhhM, KaelinWG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95(20) (1998), 11661-11666.
47. Ferchichi I, Stambouli N, Marrackchi R, Arlot Y, Prigent C, Fadiel A, Odunsi K, Ben Ammar Elgaaied A, Hamza A. Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase, J Phys Chem B 114(3) (2010), 1486-1497.
48. Ferchichi I, Arlot Y, Prigent C, Benammar Elgaaied A. Aurora-A kinase interact with and phosphorylate pVHL, Biologia 67(5) (2012), 1026-1030.